Online citations, reference lists, and bibliographies.
← Back to Search

Antiretroviral Treatment Simplification With Nevirapine In Protease Inhibitor-experienced Patients With Hiv-associated Lipodystrophy: 1-year Prospective Follow-up Of A Multicenter, Randomized, Controlled Study.

L. Ruiz, E. Negredo, P. Domingo, R. Paredes, E. Francia, M. Balagué, S. Gel, A. Bonjoch, C. Fumaz, S. Johnston, J. Romeu, J. Lange, B. Clotet
Published 2001 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
BACKGROUND: Simpler and less toxic antiretroviral strategies are needed to maximize treatment compliance without sacrificing potency, at least for drug-experienced HIV-infected patients currently on regimens containing protease inhibitors (PIs). Small nonrandomized studies have suggested a beneficial role of PI-sparing regimens on lipodystrophy. OBJECTIVES: To assess the virologic, immunologic, and clinical benefit of switching the PI to nevirapine in patients with HIV-associated lipodystrophy and sustained viral suppression before entry in the study. DESIGN: Open-labeled, prospective, randomized, multicenter study. SETTING: Seven reference inpatient centers for HIV/AIDS in Spain. PATIENTS: One hundred six HIV-infected adults with clinically evident lipodystrophy who sustained HIV-RNA suppression for at least 6 months with PI-containing antiretroviral combinations. INTERVENTION: Replacement of the PI with nevirapine during 48 weeks (Group A) versus continuing the prior PI (Group B). MEASUREMENTS: Several virologic and immunologic analyses, standard and specific biochemical tests, and anthropometric and dual X-ray absorptiometry measurements. RESULTS: At week 48, an HIV-1 RNA level <400 copies/ml was maintained in 79% and 77% of patients in Groups A and B, respectively, whereas 74% and 72% of patients had viral load levels <50 copies/ml. Absolute CD4+ counts significantly increased in both groups compared with baseline values, and a significant decrease in CD38+CD8+ cells was observed in Group A (p <.01) but not in group B. Overall, no significant changes in anthropometric or body shape measurements were found after 48 weeks. Fasting total cholesterol and triglyceride levels decreased in Group A (but not in Group B) compared with baseline values (p <.05), although no significant differences were seen between groups at the end of the study. Subjects in Group A reported a better quality of life (QOL) index than controls (p <.001), with the main reason reported being the greater simplicity of the new drug regimen. CONCLUSIONS: Protease inhibitor-sparing regimens, including nevirapine, seem to be an effective alternative for PI-experienced patients. Nevirapine-based triple therapies allow maintained control of HIV-1 RNA levels and improve the immunologic response at 48 weeks of follow-up in patients with prior sustained virologic suppression. The switch to nevirapine significantly improved the lipidic profile in Group A, although there were no differences between groups at the end of the study. Additionally, no significant changes were seen in terms of lipodystrophy-related body shape changes 1 year after the PI substitution. Finally, nevirapine-containing regimens have a simpler dosing schedule, and this facilitates high adherence and improves QOL.
This paper references
10.1097/00005650-199108000-00011
A Health Status Questionnaire Using 30 Items From The Medical Outcomes Study: Preliminary Validation in Persons With Early HIV Infection
A. Wu (1991)
10.1111/J.1475-097X.1991.TB00662.X
Validation of body composition by dual energy X-ray absorptiometry (DEXA).
J. Haarbo (1991)
10.1001/JAMA.1996.03540110036029
A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction.
M. Stampfer (1996)
10.1128/jcm.35.5.1278-1280.1997
A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity
J. Mulder (1997)
10.1056/NEJM199803263381301
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.
F. Palella (1998)
10.1016/S0140-6736(97)11443-X
“Buffalo hump” in men with HIV-1 infection
J. Lo (1998)
10.1177/135965359800300302
Management of Antiretroviral Therapy for HIV Infection: Modelling when to Change Therapy
R. D'Amato (1998)
10.1161/01.CIR.97.11.1029
Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study.
J. Jeppesen (1998)
10.1016/S0140-6736(98)03201-2
Changing patterns of mortality across Europe in patients infected with HIV-1
A. Mocroft (1998)
10.1097/00002030-199807000-00003
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
A. Carr (1998)
10.1097/00002030-199811000-00007
Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy
F. Bouscarat (1998)
10.1086/314831
Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with
A. Arnó (1999)
10.1097/00002030-199905070-00009
Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.
E. Martinez (1999)
10.1016/S0140-6736(98)08468-2
Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study
A. Carr (1999)
10.1056/NEJM199905273402101
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
L. Zhang (1999)
10.1038/8394
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
D. Finzi (1999)
10.1097/00002030-199911120-00008
Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy.
P. Domingo (1999)
10.1097/00002030-199903110-00004
Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy.
C. Gervasoni (1999)
10.1097/00002030-199909100-00009
A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.
T. Saint-Marc (1999)
10.1097/00002030-200007070-00002
Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
S. Mallal (2000)
10.1097/00002030-200001070-00005
Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO* study
T. Saint-Marc (2000)
10.1097/00002030-200009080-00008
Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy
H. Hatano (2000)
10.1097/00126334-200011010-00003
Prospective Randomized Two‐Arm Controlled Study To Determine the Efficacy of a Specific Intervention To Improve Long‐Term Adherence to Highly Active Antiretroviral Therapy
A. Tuldrà (2000)
10.1097/00002030-200005050-00006
Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy
P. Barreiro (2000)



This paper is referenced by
10.1002/cphy.c160028
Adipose Tissue in HIV Infection.
J. Koethe (2017)
Metabolic and Skeletal Complications of HIV Infection
C. Morse (2017)
Contemporary role of nevirapine in HIV treatment.
L. Coster (2012)
10.1093/jac/dks227
Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.
J. Burgos (2012)
Combination antiretroviral therapy -associated lipodystrophy : insights into pathogenesis and treatment
K. Sevastianova (2011)
10.2217/HIV.10.47
Switching antiretroviral therapy to minimize metabolic complications.
J. Lake (2010)
10.1016/J.EIMC.2010.03.002
Documento de consenso del Grupo de Estudio de Sida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (actualización enero 2010)
Panel de expertos de Gesida (2010)
Clinical Implications of Minority HIV-1 Resistant Variants
Roger Paredes i Deiros (2009)
Strategies to limit the metabolic complications of treatment for HIV infection
M. Vonderen (2009)
10.1007/978-1-60327-297-1_34
HIV Therapeutics: Antiretroviral Drugs and Immune-Based Therapies
V. Georgiev (2009)
10.1111/j.1468-1293.2008.00627.x
Switching from suppressive protease inhibitor‐based regimens to nevirapine‐based regimens: a meta‐analysis of randomized controlled trials
J. Ena (2008)
10.1016/S1730-1270(10)60061-6
The role of nevirapine in the antiretroviral therapy
M. Lemańska (2008)
10.1111/j.1468-1293.2008.00552.x
Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts *
E. de Lazzari (2008)
Risk for immune-mediated liver reactions by nevirapine revisited.
J. Medrano (2008)
10.1097/MLG.0b013e318064e8ab
HIV‐Associated Facial Lipoatrophy: Establishment of a Validated Grading Scale
E. Funk (2007)
10.1097/COH.0b013e3281e72ca0
Antiretroviral therapy-induced lipid alterations: in-vitro, animal and human studies
P. Mallon (2007)
10.1517/14656566.8.12.1871
Strategies in the treatment of HIV-1-associated adipose redistribution syndromes
María del Mar Gutierrez (2007)
10.1016/J.ATHEROSCLEROSIS.2005.09.025
Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis.
S. Fisher (2006)
10.1007/978-1-59745-085-0_10
Mitochondrial Toxicity and Lipodystrophy
G. McComsey (2006)
10.1007/978-1-59745-085-0_15
Vertical Transmission of HIV and Therapeutic Interventions
S. Cu-Uvin (2006)
10.1157/13095376
Alteraciones lipídicas y riesgo cardiovascular asociado a la terapia antirretroviral
M. Masiá-Canuto (2006)
10.2174/157016206775197664
Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection.
G. Bárbaro (2006)
10.1159/000093034
Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome and Cardiovascular Risk
G. Barbaro (2006)
10.3844/AJIDSP.2006.159.166
Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-nucleoside Reverse Transcriptase Inhibitors.
M. Rao (2006)
10.1155/2005/303141
HIV-associated lipodystrophy syndrome: A review of clinical aspects.
J. Baril (2005)
10.1016/S0151-9638(05)79330-3
La chirurgie et les produits de comblement au secours de la stigmatisation
A. Lascaux (2005)
10.1111/j.1468-1293.2005.00320.x
A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load
JA Arranz Caso (2005)
10.1157/13074743
Estrategias terapéuticas en la infección por el virus de la inmunodeficiencia humana
P. Barreiro (2005)
10.1016/J.IDC.2005.05.006
Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
E. Leonard (2005)
10.2310/6650.2005.00001
Regional Body Fat Distribution in HIV-Infected Patients with Lipodystrophy
W. Dinges (2005)
10.1016/S0140-6736(04)15489-5
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial
A. Carr (2004)
10.1310/XP75-7VJ5-HML2-YF1W
Update on HIV Lipodystrophy
S. Kravcik (2004)
See more
Semantic Scholar Logo Some data provided by SemanticScholar